Glioma - Pipeline Review, Q3 2011

Glioma - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Glioma - Pipeline Review, Q3 2011', provides an overview of the Glioma therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. 'Glioma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glioma.
- A review of the Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glioma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glioma pipeline depth and focus of Glioma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glioma Overview
Therapeutics Development
An Overview of Pipeline Products for Glioma
Glioma Therapeutics under Development by Companies
Glioma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Glioma Therapeutics - Products under Development by Companies
Glioma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Glioma Therapeutics Development
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Antigenics, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
YM BioSciences Inc.
Light Sciences Oncology, Inc.
Ark Therapeutics Group plc
Eisai Co., Ltd.
Pfizer Inc.
Cell Therapeutics, Inc.
Exelixis, Inc.
Alfacell Corporation
Bayer AG
Attenuon, LLC
Geron Corporation
Circadian Technologies Limited
Sareum Holdings plc
Antisense Pharma GmbH
NovaRx Corporation
immatics biotechnologies GmbH
Advantagene, Inc.
Ascenta Therapeutics, Inc.
Hawthorn Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc.
Burzynski Research Institute, Inc.
Biotica Technology Ltd
OncoMune, LLC
TVAX Biomedical, LLC
Lipopharma
AVEO Pharmaceuticals, Inc.
Direct Therapeutics, Inc.
n.v. BRUCELLS s.a.
Eurofarma
Tocagen Inc
Glioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E7080 - Drug Profile
Sagopilone - Drug Profile
Vandetanib - Drug Profile
Prophage - Drug Profile
AZD8055 - Drug Profile
IMA950 - Drug Profile
Polo-Like Kinase 1 - Drug Profile
Scavidin - Drug Profile
AC 03-636 - Drug Profile
TEMODAR - Drug Profile
Temozolomide + Radiation Therapy - Drug Profile
Temozolomide + Tamoxifen + Carboplatin + Radiation Therapy - Drug Profile
Temozolomide + Radiation Therapy - Drug Profile
Pentoxifylline + Hydroxyurea + Radiation Therapy - Drug Profile
Panobinostat - Drug Profile
RAD001 - Drug Profile
Bevacizumab + Irinotecan + Carboplatin - Drug Profile
Minerval - Drug Profile
Nimotuzumab - Drug Profile
Lomustine + Radiation Therapy - Drug Profile
cladribine + radiation therapy - Drug Profile
Temodar + Topotecan - Drug Profile
Thiotepa + Etoposide + Carboplatin - Drug Profile
Capecitabine + Radiation Therapy - Drug Profile
R115777 + Radiation Therapy - Drug Profile
O6-Benzylguanine + Temozolomide - Drug Profile
carmustine + mercaptopurine + streptozocin - Drug Profile
carmustine + irinotecan - Drug Profile
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile
Carmustine + Temozolomide - Drug Profile
Autologous Natural Killer Cell + Natural Killer T Cell Immunotherapy - Drug Profile
Dendritic Vaccine Pulsed With Multiple Peptides - Drug Profile
Pegintron - Drug Profile
RAD001 - Drug Profile
Temozolomide - Drug Profile
lapatinib ditosylate - Drug Profile
romidepsin - Drug Profile
Xeloda - Drug Profile
AMG 102 + Avastin - Drug Profile
Radiotherapy + Temozolomide - Drug Profile
WT1 Peptide-Based Vaccine + Temozolomide + Radiation Therapy - Drug Profile
Aminolevulinic acid - Drug Profile
RAD001 - Drug Profile
Cilengitide + Radiation Therapy - Drug Profile
Temozolomide + Bevacizumab - Drug Profile
RO4929097 + Temozolomide + Radiation therapy - Drug Profile
Celecoxib + Temozolomide + Dendritic Cell Vaccine + Radiation Therapy - Drug Profile
Bevacizumab + Temozolomide - Drug Profile
Dendritic cells + Imiquimod - Drug Profile
Thymidine + Carboplatin - Drug Profile
Nimotuzumab + Temozolomide + Radiation Therapy - Drug Profile
Pioglitazone + Rofecoxib + Capecitabine - Drug Profile
Glionix - Drug Profile
Temodar - Drug Profile
Temozolomide + Isotretinoin - Drug Profile
Bevacizumab + RO4929097 - Drug Profile
Tamoxifen citrate + Bortezomib - Drug Profile
Vorinostat + Radiotherapy - Drug Profile
IMC-A12 + CCI-779 - Drug Profile
Tarceva + Rapamycin - Drug Profile
Bevacizumab + Irinotecan - Drug Profile
Bevacizumab + Enzastaurin hydrochloride - Drug Profile
ADV-TK - Drug Profile
Capecitabine + Celecoxib + Lomustine + 6-Thioguanine - Drug Profile
Capecitabine + Celecoxib + Temozolomide + 6-Thioguanine - Drug Profile
Carmustine + Irinotecan Hydrochloride - Drug Profile
carmustine + efaproxiral - Drug Profile
Peg-Intron + Thalidomide - Drug Profile
Etoposide phosphate + Melphalan + Carboplatin + Sodium thiosulfate + Filgrastim + Pegfilgrastim - Drug Profile
bevacizumab + carmustine - Drug Profile
Enzastaurin + Temozolomide - Drug Profile
ZD6474 + Carboplatin - Drug Profile
bevacizumab + irinotecan + Radiation theraphy - Drug Profile
cintredekin besudotox - Drug Profile
Erlotinib hydrochloride + Isotretinoin - Drug Profile
gefitinib + radiation therapy - Drug Profile
CPT-11 + Temodar - Drug Profile
Vincristine + Etoposide + Radiation therapy - Drug Profile
carmustine + Radiation theraphy - Drug Profile
Tarceva - Drug Profile
Temozolomide - Drug Profile
Bevacizumab + Radiation Therapy - Drug Profile
Bevacizumab + Erlotinib + Radiation Therapy - Drug Profile
Bevacizumab + Erlotinib + Temozol + Radiation Therapy - Drug Profile
Bevacizumab + Temozol + Radiation Therapy - Drug Profile
Atrasentan - Drug Profile
Bevacizumab + Irinotecan - Drug Profile
erlotinib + radiation therapy - Drug Profile
GM-K562 Cell Vaccine - Drug Profile
IL13-PE38QQR - Drug Profile
Irinotecan hydrochloride - Drug Profile
Lapatinib Ditosylate - Drug Profile
LY317615 - Drug Profile
Palonosetron - Drug Profile
Tamoxifen + Radiation therapy - Drug Profile
temozolomide + Radiation Therapy - Drug Profile
temozolomide + vorinostat - Drug Profile
Vinblastine - Drug Profile
Cetuximab - Drug Profile
LY2157299 + Temozolomide + Radiation Therapy - Drug Profile
Lenalidomide + Radiation Therapy - Drug Profile
haw mAb11 - Drug Profile
Vorinostat + Bevacizumab + Radition Therapy - Drug Profile
Bevacizumab + Radiation Therapy - Drug Profile
Opaxio + Temozolomide + Radiation Therapy - Drug Profile
Montanide ISA-51 + SVN53-67/M57-KLH + Sargramostim - Drug Profile
Tipifarnib + Radiation Therapy - Drug Profile
Dendritic Cell Vaccination + Adoptive T Cell Transfer - Drug Profile
Gefitinib + Temozolomide - Drug Profile
Vorinostat + Bevacizumab - Drug Profile
XL541 - Drug Profile
Temozolomide - Drug Profile
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile
BMS-247550 - Drug Profile
Toca 511 + Toca FC - Drug Profile
Sorafenib + Temozolomide + Radiation Therapy - Drug Profile
Autologous Tumor Lysate-Pulsed DC Vaccine - Drug Profile
Nimotuzumab + Radiation Therapy - Drug Profile
AT-101 + Temodar + Radiation Therapy - Drug Profile
Panobinostat + Radiation Therapy - Drug Profile
Temozolomide - Drug Profile
Riluzole + Memantine - Drug Profile
NSC 74859 - Drug Profile
Arsenic Trioxide - Drug Profile
Mesenchymal Stem Cells - Drug Profile
Interferon-Beta + Temozolomide + Radiation Therapy - Drug Profile
BCL-003 - Drug Profile
AMD3100 + Avastin - Drug Profile
UK1 + Celecoxib - Drug Profile
Bevacizumab + Fotemustine - Drug Profile
Sunitinib - Drug Profile
BIBF 1120 - Drug Profile
Atengenal + Astugenal - Drug Profile
Dendritic Cell Activated Cytokine Induced Killer Cell + Dendritic Cell - Drug Profile
Glioma Therapeutics – Drug Profile Updates
Glioma Therapeutics - Discontinued Products
Glioma - Featured News
Jun 07, 2011: Tocagen's First-in-Human Clinical Trial Of Toca 511 Enrolling Patients With High Grade Glioma
Jun 06, 2011: New Data From Phase II Brain Cancer Study With Prophage Series G-200 Shows Improved Overall Survival
May 18, 2011: Agenus To Present New Data From Prophage G-200 Phase II Recurrent Glioma Trial At ASCO 2011 Annual Meeting
May 12, 2011: Cell Therapeutics Announces New OPAXIO Data Selected For Oral Discussion Sessions At 2011 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Glioma, Q3 2011
Products under Development for Glioma – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
Viralytics Ltd., 2011
GlaxoSmithKline plc, 2011
Antigenics, Inc., 2011
Daiichi Sankyo Company, Ltd, 2011
Merck & Co., Inc., 2011
YM BioSciences Inc., 2011
Light Sciences Oncology, Inc., 2011
Ark Therapeutics Group plc, 2011
Eisai Co., Ltd., 2011
Pfizer Inc., 2011
Cell Therapeutics, Inc., 2011
Exelixis, Inc., 2011
Alfacell Corporation, 2011
Bayer AG, 2011
Attenuon, LLC, 2011
Geron Corporation, 2011
Circadian Technologies Limited, 2011
Sareum Holdings plc, 2011
Antisense Pharma GmbH, 2011
NovaRx Corporation, 2011
immatics biotechnologies GmbH, 2011
Advantagene, Inc., 2011
Ascenta Therapeutics, Inc., 2011
Hawthorn Pharmaceuticals, Inc., 2011
Reata Pharmaceuticals, Inc., 2011
Burzynski Research Institute, Inc., 2011
Biotica Technology Ltd, 2011
OncoMune, LLC, 2011
TVAX Biomedical, LLC, 2011
Lipopharma, 2011
AVEO Pharmaceuticals, Inc., 2011
Direct Therapeutics, Inc., 2011
n.v. BRUCELLS s.a., 2011
Eurofarma, 2011
Tocagen Inc, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Glioma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Glioma, Q3 2011
Products under Development for Glioma – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011